Inflarx (IFRX) Earns Outperform Rating from Analysts at Leerink Swann

Leerink Swann assumed coverage on shares of Inflarx (NASDAQ:IFRX) in a research note issued to investors on Monday morning, Marketbeat reports. The brokerage issued an outperform rating and a $31.00 price objective on the stock.

Separately, J P Morgan Chase & Co began coverage on Inflarx in a report on Monday. They issued an overweight rating and a $30.00 target price for the company.

Inflarx (NASDAQ:IFRX) traded down $1.08 during trading on Monday, hitting $17.58. The company’s stock had a trading volume of 92,900 shares, compared to its average volume of 57,095. Inflarx has a twelve month low of $14.47 and a twelve month high of $22.48.

COPYRIGHT VIOLATION NOTICE: “Inflarx (IFRX) Earns Outperform Rating from Analysts at Leerink Swann” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2017/12/07/inflarx-ifrx-earns-outperform-rating-from-analysts-at-leerink-swann.html.

Inflarx Company Profile

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company’s primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases.

What are top analysts saying about Inflarx NV? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Inflarx NV and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit